Vizsgálati helyszín

Pratia Pardubice a.s.

Pardubice I, CsehországEU-13 felzárkózó országMég nincs intézményhez kötve

17futó vizsgálat
14lezárt vizsgálat
0a helyszín által az elmúlt 60 napban megerősített vizsgálat
–nyelv nincs megadva

A helyszín még egy vizsgálatot sem erősített meg.

Futó vizsgálatok

Még nem toboroz
A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure
NCT07584967· 2. fázis· Forrás
Még nem toboroz
A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)
2025-525033-31-00· 2. fázis· Forrás
Toboroz
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058· 3. fázis· Forrás
Fut, nem toboroz
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
NCT07400653· 3. fázis· Forrás
Toboroz
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931· 3. fázis· Forrás
Toboroz
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
NCT07441395· 2. fázis· Forrás
Fut, nem toboroz
A study to investigate the efficacy and safety of TRIV-509 compared with placebo in adults with moderate to severe atopic dermatitis
2025-522113-35-00· 2. fázis· Forrás
Fut, nem toboroz
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NCT07219602· 3. fázis· Forrás
Fut, nem toboroz
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
NCT07217015· 2. fázis· Forrás
Toboroz
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
NCT07216027· 2. fázis· Forrás
Fut, nem toboroz
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
2024-516652-18-00· 3. fázis· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
NCT06887192· 2. fázis· Forrás
Toboroz
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483· 3. fázis· Forrás
Fut, nem toboroz
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· 3. fázis· Forrás
Fut, nem toboroz
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076· 3. fázis· Forrás
Fut, nem toboroz
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT06136741· 2. fázis· Forrás
Leállították
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT06058156· 2. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

Lezárult
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
NCT06973291· 3. fázis· Forrás
Toboroz
Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis
NCT06833749· 2. fázis· Forrás
Lezárult
A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-naïve participants with early rheumatoid arthritis and active inflammation.
2024-514981-37-00· 2. fázis· Forrás
Lezárult
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT06602219· 2. fázis· Forrás
Lezárult
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis
2023-506664-14-00· 3. fázis· Forrás
Lezárult
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
NCT06586112· 3. fázis· Forrás
Toboroz
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.
NCT06239311· 3. fázis· Forrás
Lezárult
Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic Dermatitis
2022-502997-18-00· 1. fázis· Forrás
Lezárult
A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis
NCT06073093· 2. fázis· Forrás
Lezárult
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
NCT06108544· 3. fázis· Forrás
Lezárult
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
NCT05748483· 3. fázis· Forrás
Lezárult
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
NCT04686136· 3. fázis· Forrás
Lezárult
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
NCT04436640· 3. fázis· Forrás
Lezárult
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
NCT04009499· 3. fázis· Forrás

Helyszínadatok: EU CTIS (euclinicaltrials.eu)Frissítve: 2026. nov. 12.

Hibát jelzek